Allogene Therapeutics (ALLO) vs Inhibikase Therapeutics (IKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Inhibikase Therapeutics (IKT) has outperformed Allogene Therapeutics (ALLO) over the past year, losing 11.4% versus a loss of 49.0%. Over five years, IKT leads with a -89.3% price change compared with -96.5% for ALLO. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $185.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | IKT |
|---|---|---|
| Share price | $0.6277 | $1.32 |
| Market cap | $217.48M | $185.16M |
| 1-day change | -5.88% | +1.54% |
| YTD return | -54.18% | -35.61% |
| 1-year return | -48.97% | -11.41% |
| 5-year return | -96.51% | -89.32% |
| EPS (TTM) | $-0.61 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-190.89M | $-48.26M |
| 52-week high | $4.46 | $2.61 |
| 52-week low | $0.6192 | $1.28 |
| Distance from 52-week high | -85.93% | -49.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +320.45% |
| Average volume | 7.69M | 584.27K |
| Shares outstanding | 346.47M | 140.27M |
| Employees | 150 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IKT has outperformed ALLO by 37.6 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
ALLO vs IKT FAQ
Which is bigger, Allogene Therapeutics or Inhibikase Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $185.16M for Inhibikase Therapeutics (IKT).
Which stock has performed better over the past year, ALLO or IKT?
IKT returned -11.41% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Inhibikase Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.